A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania infantum

• Published in: Experimental parasitology 2020-07, Vol.214, p.107903, Article 107903
• Main Authors: Kasabalis, D., Chatzis, M.K., Apostolidis, K., Petanides, T., Athanasiou, L.V., Xenoulis, P.G., Mataragka, A., Ikonomopoulos, J., Leontides, L.S., Saridomichelakis, M.N.
• Format: Article
• Language: English
• Subjects: Allopurinol; Allopurinol - therapeutic use; Aminosidine; Animals; Dog; Dog Diseases - drug therapy; Dog Diseases - parasitology; Dogs; Drug Therapy, Combination; Female; Injections, Subcutaneous - veterinary; Leishmania infantum - drug effects; Leishmaniasis, Visceral - drug therapy; Leishmaniasis, Visceral - veterinary; Leishmaniosis; Male; Meglumine antimonate; Meglumine Antimoniate - therapeutic use; Paromomycin; Paromomycin - therapeutic use; Trypanocidal Agents - therapeutic use
• ISSN: 0014-4894; 1090-2449; 1090-2449
• DOI: 10.1016/j.exppara.2020.107903

The aim of this 6-month, randomized, blinded, controlled clinical trial was to compare the efficacy and safety of aminosidine-allopurinol combination with that of meglumine antimoniate-allopurinol combination for the treatment of leishmaniosis in dogs without stage III or IV chronic kidney disease. Forty client-owned dogs were randomly assigned to group A [n = 20; aminosidine (15 mg/kg, subcutaneously, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)] or group B [(n = 20; meglumine antimoniate (100 mg/kg SC, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)]. Clinical and clinicopathological evaluations, parasitic load measurement (lymph node and bone marrow microscopy, bone marrow real-time PCR), specific serology and leishmanin skin test (LST) were performed at baseline (time 1) and after 14 (time 2), 28 (time 3), 60 (time 4) and 180 (time 5) days. Both treatments were safe and resulted in significant clinical and clinicopathological improvement, reduction of parasitic load and of indirect immunofluorescence antibody test (IFAT) titer and induction of positive LST. There was no significant difference between groups with regards to the primary outcome measures of the trial that included the proportion of dogs that presented severe treatment-related side effects, were cured and were parasitologically negative at time 5. However, some (proportion of dogs that presented no clinical signs, no hyperglobulinemia and negative serology at time 5) secondary outcome measures showed significant differences in favor of the meglumine antimoniate-allopurinol treatment arm. Treatment-related death occurred in one dog in each group, while injection site reactions appeared at a similar frequency in both groups. Due to the differences in some secondary outcome measures in association with the low power of this trial, it cannot be definitively concluded that the two treatments are equally effective. Therefore, the aminisodine-allopurinol combination cannot be proposed as a first-line treatment of CanL but rather as a second-line treatment that may be particularly useful to avoid repeated administration of meglumine antimoniate and in countries where the latter is not available or registered. [Display omitted] •Aminosidine-allopurinol was as safe as meglumine antimoniate-allopurinol.•Cure rates did not differ between the two treatment arms.•Rate of negative parasitological examinations did not differ